The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy

Tumor Biology ◽  
2014 ◽  
Vol 36 (3) ◽  
pp. 1519-1527 ◽  
Author(s):  
M. Tampellini ◽  
A. Ottone ◽  
I. Alabiso ◽  
C. Baratelli ◽  
L. Forti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Time Dependent ◽  
Prognostic Role ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Colorectal Cancer Patients

Prognostic value of incidental betablockers use in metastatic colorectal cancer patients receiving first-line treatment.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14610-e14610
Author(s):  
Michela Del Prete ◽  
Riccardo Giampieri ◽  
Mario Scartozzi ◽  
Elena Maccaroni ◽  
Luca Faloppi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Response Rate ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
First Line Therapy ◽  
Line Therapy ◽  
Colorectal Cancer Patients

e14610 Background: Preclinical and retrospective studies suggested antitumor activity for the incidental use of betablockers in various tumour types. Data regarding colorectal cancer are lacking. We assessed the correlation between the incidental use of betablockers and clinical outcome in colorectal cancer patients receiving first-line therapy. Methods: 235 patients treated with first-line chemotherapy alone (128 patients) and with Bevacizumab (107 patients) were analysed. Patients were stratified for betablockers use, age, sex, site of metastases, previous adjuvant chemotherapy and ECOG performance status. Results: 29 patients (12%) were on treatment with betablockers at the time of first-line therapy: 20 (16%) in the chemotherapy alone group and 9 in the bevacizumab group (8%). In both groups patients receiving or not betablockers were similar for all main clinical characteristics. In the chemotherapy alone group, patients receiving betablockers showed an improved response rate (60% vs. 33%, p=0.044) and overall survival (mOS 41.3 vs 25.7 months, p=0.03, HR:2.26, 95% CI: 1.05-3.24). Only a trend for improved progression free survival was noticed. In the 107 patients receiving chemotherapy with bevacizumab a trend towards a worse overall survival was seen for patients receiving betablockers, although this was not statistically significant (mOS 16 vs 23.7 months, p=0.26, HR:0.64, 95% CI: 0.22-1.49). No significant differences were seen in regards of progression free survival or different response rate patterns between the two groups. Conclusions: Our analysis confirms a potential prognostic role for the use of betablockers in colorectal cancer patients treated with chemotherapy. Our findings are in line with preclinical studies suggesting that beta-adrenergic signalling may regulate cancerogenesis and tumor invasiveness. Our analysis suggests a potential worse outcome for patients on betablockers receiving Bevacizumab-based treatment, although the small number of patients precludes any definitive conclusion. We suggest that in future prospective trials the incidental use of betablockers will be considered a stratification factor for clinical outcome.

scholarly journals The ‘real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study

2014 ◽  
Vol 54 (2) ◽  
pp. 164-170 ◽  
Author(s):  
Ariel Hammerman ◽  
Sari Greenberg-Dotan ◽  
Erez Battat ◽  
Ilan Feldhamer ◽  
Haim Bitterman ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Retrospective Cohort ◽  
Real Life ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Life Impact ◽  
Colorectal Cancer Patients

Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15524-e15524
Author(s):  
Hua Cao ◽  
Xinyi Liu ◽  
Yixin Chen ◽  
Pan Yang ◽  
Tanxiao Huang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Cancer Patients ◽  
Circulating Tumor Dna ◽  
First Line ◽  
Tissue Samples ◽  
First Line Therapy ◽  
Line Therapy ◽  
Colorectal Cancer Patients ◽  
Tumor Dna

e15524 Background: Colorectal cancer (CRC) is a highly lethal disease worldwide. The majority of patients receiving targeted therapy or chemotherapy develop drug resistance, while its molecular mechanism remains to be elucidated. The plasma circulating tumor DNA (ctDNA) exhibited the potential in identifying gene variations and monitoring drug resistance in CRC treatment. Methods: In this study, we monitored the ctDNA mutational changes in advanced CRC patients underwent first-line therapy with bevacizumab and cetuximab combined with chemotherapy. The mutation spectrum of 43 patients was established by a 605-gene next-generation sequencing (NGS) panel. Results: The baseline measurement shows that genes with the highest mutation frequency were TP53 (74%), APC (58%), KRAS (40%), SYNE1 (33%), LRP1B (23%), TOP1 (23%) and PIK3CA (21%). Mutations in TP53, APC and KRAS were detected in 29 paired plasma and tissue samples with the consistency of 81%, 67% and 42%, respectively. Clinically targetable gene mutations, such as APC, RNF43, SMAD4, BRAD1, KRAS, RAF1, and TP53, were also identified in ctDNA. The overall consistency between ctDNA and tissue samples was 54.6%. Alleviation of mutational burden in BRAF, KRAS, AMER1 and other major driving genes was observed following the first-line therapy. Patients with KRAS and TP53 mutations in tissues appeared to benefit more than the wild-type counterpart. The dynamic change of plasma mutation status was consistent with the tissue tumor burden and was closely correlated with disease progression. Conclusions: ctDNA monitoring is a useful method for molecular genotyping of colorectal cancer patients. Dynamic changes in resistance can be sensitively monitored by gene variation status, which potentially helps to develop treatment strategy.

Sign in / Sign up

Export Citation Format

Share Document